|Articles|January 16, 2023
DeepIntent Celebrates Year-Over-Year Growth as Marketers Invest in CTV
Adding more than 100 employees to its team in 2022, the company's growth has outpaced growth in the broader healthcare advertising segment, as pharmaceutical marketers increasingly embrace digital advertising, particularly on CTV.
Advertisement
DeepIntent, a healthcare advertising technology company built to influence better patient health and business outcomes, announced it has reached a significant milestone, achieving growth for the fifth consecutive year and a triple-digit percentage growth rate across connected television (CTV) campaigns.
In 2022, DeepIntent experienced triple-digit growth in CTV investment on its demand side platform, making CTV one of the fastest-growing channels for the hundreds of pharmaceutical brands now using the DeepIntent Healthcare Advertising Platform.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
3
Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint
4
Pharmaceutical Executive Daily: U.S. & U.K. Agree to 0% Tariffs on Pharmaceutical Products
5
